Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, Baste-Rotllan N, Bidault F, Guigay J, Le Tourneau C, Saada-Bouzid E, Even C. Saleh K, et al. Eur J Cancer. 2019 Nov;121:123-129. doi: 10.1016/j.ejca.2019.08.026. Epub 2019 Sep 28. Eur J Cancer. 2019. PMID: 31574417
High incidence of cetuximab-related infusion reactions in head and neck patients.
Palomar Coloma V, Bravo P, Lezghed N, Mayache-Badis L, Herrera Gómez RG, Iacob M, Nicouleau L, Desmaris R, Tao Y, Leibu C, Matias M, Lemare F, Even C, Annereau M, Ferté C. Palomar Coloma V, et al. ESMO Open. 2018 Jul 23;3(5):e000346. doi: 10.1136/esmoopen-2018-000346. eCollection 2018. ESMO Open. 2018. PMID: 30094066 Free PMC article.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A, Herrera Gómez RG, Rossoni C, Dercle L, Ammari S, Girault I, Roy S, Scoazec JY, Vagner S, Janot F, Eggermont AMM, Robert C. Moya-Plana A, et al. Cancer Immunol Immunother. 2019 Jul;68(7):1171-1178. doi: 10.1007/s00262-019-02351-7. Epub 2019 Jun 7. Cancer Immunol Immunother. 2019. PMID: 31172258 Free PMC article.
[2020 oncology update].
Dei Tos G, Galli Vareia I, Huber A, Wolf B, Diciolla A, Herrera Gomez RG, Wagner D, Digklia A, Bouchaab H, Cristina V, Stravodimou A, Zaman K, Sarivalasis A, Berthold D, Peters S, Perrinjaquet C, Kloepper J, Jankovic J. Dei Tos G, et al. Among authors: herrera gomez rg. Rev Med Suisse. 2021 Jan 27;17(723):201-205. Rev Med Suisse. 2021. PMID: 33507661 French.
15 results